Martin Brenner has taken on the role of CEO and CSO of iBio, Inc., where he is leading a collaboration with AstralBio focused on target discovery.
4 reports, 2 independent
Updated Aug 28
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Martin Brenner has taken on the role of CEO and CSO of iBio, Inc., where he is leading a collaboration with AstralBio focused on target discovery.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Marshall Wace participated in iBio's public offering on August 25, 2025.Sub-event
Martin Brenner joins iBio as CEO/CSO and collaborates with AstralBio on target discovery.1 source
Keep exploring
The entities involved
-
Martin Brenner
researcher (ORCID 0000-0002-6669-8590)
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody ther
- Unknown outlet